Low Serum Ficolin-3 Levels on Admission Are Associated With Poor Outcomes After Severe Traumatic Brain Injury
Prognostic Value of Serum Ficolin-3 Levels After Severe Traumatic Brain Injury:A Pilot Study
1 other identifier
observational
128
0 countries
N/A
Brief Summary
The current study was designed to investigate the change of serum ficolin-3 levels and assess the prognostic predictive effect of serum ficolin-3 levels in the patients with severe traumatic brain injury.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Apr 2011
Longer than P75 for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 2011
CompletedPrimary Completion
Last participant's last visit for primary outcome
July 1, 2014
CompletedStudy Completion
Last participant's last visit for all outcomes
February 1, 2015
CompletedFirst Submitted
Initial submission to the registry
July 18, 2015
CompletedFirst Posted
Study publicly available on registry
July 29, 2015
CompletedJuly 29, 2015
July 1, 2015
3.3 years
July 18, 2015
July 26, 2015
Conditions
Outcome Measures
Primary Outcomes (1)
Mortality after severe traumatic brain injury
Using structure telephone interviews, follow-up was performed by 1 doctor who was blinded to clinical information.
Follow-up of 6 months
Secondary Outcomes (1)
Unfavorable outcome after severe traumatic brain injury
Follow-up of 6 months
Study Arms (1)
sTBI group
The patients with isolated head trauma and postresuscitation GCS score of 8 or less.
Eligibility Criteria
The patients with isolated head trauma and postresuscitation Glasgow Coma Scale score of 8 or less.
You may qualify if:
- Isolated head trauma
- Postresuscitation Glasgow Coma Scale score of 8 or less.
You may not qualify if:
- Less than 18 years of age
- Admission time \> 6 hours
- Previous head trauma
- Neurological disease including ischemic or hemorrhagic stroke
- Use of antiplatelet or anticoagulant medication
- Diabetes mellitus
- Hypertension
- Presence of other prior systemic diseases including uremia, liver cirrhosis, malignancy, and chronic heart or lung disease
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Biospecimen
All blood samples from the patients at admission were collected in the tubes and centrifuged within 30 minutes at 1,000\*g for 15 minutes. The serum was removed and frozen at -70°C until measurement.
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Department of Neurosurgery
Study Record Dates
First Submitted
July 18, 2015
First Posted
July 29, 2015
Study Start
April 1, 2011
Primary Completion
July 1, 2014
Study Completion
February 1, 2015
Last Updated
July 29, 2015
Record last verified: 2015-07